Durable remissions were associated with a high tumor mutation burden, evidence of DNA repair disruption (via BRCA2 mutations and EMSY overexpression), and tumor infiltration of PD‐L1 expressing immune cells. This evidence concerns the gene CD274 and neoplasm.